Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379029 | 0.75 | NPC1 (0.33) | GAARAB9ANPC1 | |
| SCHEMBL25929714 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23232310 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12886033 | 0.72 | SMN1; SMN2 (0.42) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5379335 | 0.72 | SREBF2 (0.31) | RAB9AMAPTL3MBTL1 | |
| SCHEMBL19070031 | 0.71 | NOS1 (0.36) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25933555 | 0.71 | RAB9A (0.37) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14367713 | 0.69 | ADORA2A (0.48) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL697727 | 0.69 | TP53 (0.42) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26226198 | 0.69 | SMN1; SMN2 (0.43) | SMN1; SMN2NOS1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211680-B2 | Vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
| US-20050080058-A1 | New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | SCHERING AKTIENGESELLSCHAFT PATENTS (DE) | 2005-04-14 | — | — | US | disclosed |
| CN-1173944-C | Vitamin D-derivatives having a carbocyclic or heterocyclic substituent at C-25, method for the production thereof, intermediate products and use thereof for producing medicaments | ���ֹɷݹ�˾ | 2004-11-03 | — | — | CN | disclosed |
| US-6642218-B2 | (5Z,7E,22E)-(1S,3R,24R)-25-(5-Propyloxazol-2-yl)-26,27-cyclo -9,10-secocholesta-5,7,10(19), 22-tetraene-1,3,24-triol for treatment of diseases characterized by hyperproliferation and deficient cell differentiation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-04 | — | — | US | disclosed |
| US-6613920-B1 | 25-(5-propylimidazol-2-yl)-26,27-cyclo-9, 10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol; antagonizes the action of calcitriol in HL 60 cells; hyperprolifierative diseases of the skin, tumor diseases and precancerous stages | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-02 | — | — | US | disclosed |
| US-6600058-B1 | The invention concerns new vitamin D derivatives of general formula (I) a process for their production, their use for production of medicaments, and intermediate products used in the process. treating a patient for hyperprolifierative | SCHERING AKTIENGELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
| EP-0900198-B1 | NEW VITAMIN D DERIVATIVES WITH CARBO- OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-03-12 | — | — | EP | disclosed |
| US-20020049344-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-25 | — | — | US | disclosed |
| CN-1216978-A | Vitamin D-derivatives having a carbocyclic or heterocyclic substituent at C-25, method for the production thereof, intermediate products and use thereof for producing medicaments | SCHERING AG (DE) | 1999-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049344-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | CYP2R1, VDR, CYP24A1 | SMN1; SMN2 4868/4885NOS1 2597/4885SLC6A2 4835/4885 |
| US-20050080058-A1 | New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | VDR, CYP24A1, CYP2R1 | SMN1; SMN2 4483/4885NOS1 3645/4885SLC6A2 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.